Treating adults with acute lymphocytic leukemia: new pharmacotherapy options

References

• Jabbour E, O’Brien S, Konopleva M, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517–2528.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532–543.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl.5):v69–v82.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216–1230.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL 12/ECOG 2993 study. Blood. 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–1914.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernández-Rias JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95:589–596.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
   PubMed Web of Science ®Google Scholar
• Stumpel DJ, Schneider P, Pieters R, et al. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer. 2015;51:2008–2021.
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5:855–863.
   PubMed Web of Science ®Google Scholar
• Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–6049.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167–1173.
   PubMed Web of Science ®Google Scholar
• Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest oncology group study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukemia. Br J Haematol. 2010;151:430–434.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009;23:1121–1135.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504–3511.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Ravandi F, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson cancer center experience. Leukemia. 2014;28:973–975.
   PubMed Web of Science ®Google Scholar
• Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children’s oncology group. J Clin Oncol. 2005;23:3376–3382.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106:4253–4260.
   PubMed Web of Science ®Google Scholar
• Korycka A, Blonski JZ, Robak T. Forodesine (BCX-1777, Immucillin H) – a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem. 2007;7:976–983.
   PubMed Web of Science ®Google Scholar
• Balakrishnan K, Ravandi F, Bantia S, et al. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:458–466.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Lunning MA, Avramis VI, et al. High-grade pegylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessary predict recurrent hepatotoxicity in subsequent cycles. Blood. 2013;122:2671.
   Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76–85.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for adult ALL (GMALL) Study 07/2003. Blood. 2010;116:219–220.
   Web of Science ®Google Scholar
• Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother. 2007;8:1977–1984.
   PubMed Web of Science ®Google Scholar
• Vieira Pinheiro JP, Müller HJ, Schwabe D, etal. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol. 2001;113:115–119.
   PubMed Web of Science ®Google Scholar
• Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9:111–119.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children’s cancer group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegasparaginase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• Appel IM, Pinheiro JPV, Den Boer ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003;17:2254–2256.
   PubMed Web of Science ®Google Scholar
• Henriksen LT, Nersting J, Raja RA, et al. Cerebrospinal fluid asparagine depletion during pegylatedasparaginase therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 2014;166:213–220.
   PubMed Web of Science ®Google Scholar
• Kirkwood A, Dey A, Rowntree C, et al. Feasibility of pegylated-asparaginase (PEG-ASP) during induction in adults with acute lymphoblastic leukaemia (ALL): results from the UK phase 3 multicentre trial UKALL 14. Blood. 2013;122:3900.
   Google Scholar
• Salles G, Lepretre S, Le Gouill S, et al. A phase I dose-escalation study of mPEG-R-crisantaspase administered by intravenous infusion in adult patients with relapsed or refractory hematological malignancies. Haematologica. 2014;99(Suppl.1):279.
   Google Scholar
• Domenech C, Thomas X, Chabaud S, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153:58–65.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Leguay T, Huguet F, et al. A phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRASPALL/GRAALL-SA2-2008 study. Am JHematol. 2015;90:811–818.
   PubMed Web of Science ®Google Scholar
• Bertrand Y, Baruchel A, Thomas XG, et al. Clinical activity of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in phase III randomized trial in patients with relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol. 2015;33(issue 15S):375s.
   Google Scholar
• Offidani M, Corvatta L, Malerba L, et al. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2005;46:233–238.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96:245–252.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Thomas DA, Wang ES, et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:430–434.
   PubMed Web of Science ®Google Scholar
• Zou Y, Priebe W, Stephens LC, et al. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res. 1995;1:1369–1374.
   PubMed Web of Science ®Google Scholar
• Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother. 2008;9:301–309.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214–3218.
   PubMed Web of Science ®Google Scholar
• Boehlke L, Winter JN. Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opin Biol Ther. 2006;6:409–415.
   PubMed Web of Science ®Google Scholar
• Douer D. Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. Oncologist. 2016;21:840–847.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106:120–127.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676–683.
   PubMed Web of Science ®Google Scholar
• Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol. 2015;94:99–108.
   PubMed Web of Science ®Google Scholar
• Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098–1107.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–3879.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomized, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–2411.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). J Clin Oncol. 2010;28:6506.
   Web of Science ®Google Scholar
• Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood. 2010;116(issue 21):170.
   Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Koller PB, Kantarjian HM, et al. Phase II study of the frontline Hyper-CVAD in combination with ofatumumab for adult patients (pts) with CD-20 positive acute lymphoblastic leukemia (ALL). Blood. 2015;126(issue23):1295.
   Google Scholar
• Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with anti-CD52-positive acute leukemia. Cancer. 2006;106:2645–2651.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Isnard F, Garderet L, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol. 2013;91:315–321.
   PubMed Web of Science ®Google Scholar
• Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood. 2009;114:838.
   Web of Science ®Google Scholar
• Van Besien K, Stock W, Rich E, et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:913–921.
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Emoto C, Fukuda T, et al. A prospective study of alemtuzumab as a second line agent for steroid refractory acute graft versus host disease in pediatric and young adult allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2016. doi:10.1016/j.bbmt.2016.09.016.
   Google Scholar
• Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6:1341–1353.
   PubMed Web of Science ®Google Scholar
• Advani AS, McDonough S, Coutre S, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;165:504–509.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Huguet F, Raffoux E, et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica. 2015;100:e128–31.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Eugene T, Robillard N, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2:e108–17.
   PubMed Web of Science ®Google Scholar
• Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Invest Drugs. 2012;21:871–878.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–411.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphoblastic leukemia. Cancer. 2013;119:2728–2736.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Sasaki K, et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with acute lymphoblastic leukemia (ALL). Blood. 2015;126(issue 23):83.
   Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicenter, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Topp MS, Stein A, Gökbuget N, et al. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Haematologica. 2016;101(s1):24–25.
   Google Scholar
• Haen SP, Schmiedel BJ, Rothfelder K, et al. Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. Oncotarget. 2016;7:13013–13030.
   PubMed Web of Science ®Google Scholar
• Norris RE, Adamson PC. Clinical potency of methotrexate,aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer Chemother Pharmacol. 2010;65:1125–1130.
   PubMed Web of Science ®Google Scholar
• Sarris AH, Phan A, Duvic M, et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol. 2002;20:2876–2880.
   PubMed Web of Science ®Google Scholar
• Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy. 2006;26:641–654.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Zapata MC, Singh A, et al. Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-cell in a NOTCH-independent manner. Apoptosis. 2014;19:1616–1626.
   PubMed Web of Science ®Google Scholar
• Samon JB, Castillo-Martin M, Hadler M, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012;11:1565–1575.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464:1052–1057.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112:2020–2023.
   PubMed Web of Science ®Google Scholar
• Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759–1767.
   PubMed Web of Science ®Google Scholar
• Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738–3747.
   PubMed Web of Science ®Google Scholar
• Baker A, Gregory GP, Verbrugge I, et al. The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia. Cancer Res. 2016;76:1158–1169.
   PubMed Web of Science ®Google Scholar
• Kampen KR, Terelst A, Mahmud H, et al. Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML. Leukemia. 2014;28:589–599.
   PubMed Web of Science ®Google Scholar
• Klaus CR, Iwanowicz D, Johnston D, et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014;350:646–656.
   PubMed Web of Science ®Google Scholar
• Accordi B, Galla L, Milani G, et al. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia. 2013;27:1019–1027.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Imamura T, Yano M, et al. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promotor region. Blood Cancer J. 2014;4:e205.
   PubMed Web of Science ®Google Scholar
• Chillon MC, Gomez-Casares MT, Lopez-Jorge CE, et al. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. Leukemia. 2012;26:2360–2366.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119–122.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Sommermeyer D, Berger C, et al. Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition. Blood. 2014;124:384.
   Web of Science ®Google Scholar
• Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–1121.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Foà R. Management of adult Ph-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015:406–413.
   PubMed Web of Science ®Google Scholar
• Dombret H, Cluzeau T, Huguet F, et al. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014;9:158–164.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–1015.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–1477.
   PubMed Web of Science ®Google Scholar
• Lim SN, Joo YD, Lee KH, et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2015;90:1013–1020.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45:695–698.
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–2793.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106:458–463.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Bethge W, et al. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study. Bone Marrow Transplant. 2009;43:S48.
   Web of Science ®Google Scholar
• Nishiwaki S, Miyamura K, Kato C, et al. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res. 2010;30:2415–2418.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254–1262.
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790–5797.
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473–481.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Gökbuget N, et al. Dasatinib and low intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774–782.
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinibmesylate, dasatinib (BM-354825) and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332–2338.
   PubMed Web of Science ®Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126:746–756.
   PubMed Web of Science ®Google Scholar
• Remsing LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid cells. Leukemia. 2009;23:477–480.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potentially inhibits the T315I mutant and overcome mutation-based resistance. Cancer Cell. 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Korashad JS, De Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic myeloid leukemia responding to imatinib may identify those at risk of disease progression. J Clin Oncol. 2008;26:4806–4813.
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahisk SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428–442.
   PubMed Web of Science ®Google Scholar
• Lierman E, Smits S, Cools J, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26:1693–1695.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nature Rev Cancer. 2004;4:927–936.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kim DW, Rubin E, et al. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e238.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126(issue23):679.
   Google Scholar
• Herold T, Baldus CD, Gökbuguet N. Ph-like acute lymphoblastic leukemia in older adults. N Engl J Med. 2014;371:2235.
   PubMed Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120:3510–3518.
   PubMed Web of Science ®Google Scholar
• Eyre T, Schwab CJ, Kinstrie R, et al. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood. 2012;120:4441–4443.
   PubMed Web of Science ®Google Scholar
• Lengline E, Beldjord K, Dombret H, et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98:e146–148.
   PubMed Web of Science ®Google Scholar
• Masuzawa A, Kiyotani C, Osumi T, et al. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript. Eur J Haematol. 2014;92:263–267.
   PubMed Web of Science ®Google Scholar